Redeye has made some minor changes in its estimates following the Q1-results in Remedy. We see Remedy as a unique investment opportunity for private investors to be shareholders in one of the last remaining high-quality independent premium games studios in the world. The premium valuation is according to us justified as Remedy is an obvious takeover target.